ADVANTAN Presentation Uses - Medsafe
ADVANTAN® Data Sheet Page 2 of 9 • ADVANTAN ® cream As a low-fat formulation with a high water content, ADVANTAN® cream is particularly suitable for acute and subacute weeping stages of eczema, for
Download ADVANTAN Presentation Uses - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzRedipred – Data Sheet Page 3 of 11 dosage appear to be important factors in determining suppression of the pituitary adrenal axis and response to stress on cessation of steroid treatment.
Related documents
CONSUMER MEDICINE INFORMATION - Medsafe
www.medsafe.govt.nzADVANTAN ® Consumer Medicine Information Page 2 of 6. Before you use ADVANTAN ® Do not use ADVANTAN ® if you have any of the conditions listed below.
6．うっ滞性皮膚炎 - derm-hokudai.jp
www.derm-hokudai.jp8．汗疱，異汗性湿疹 119 7 8．汗疱，異汗性湿疹 pompholyx，dyshidrotic eczema 手掌・足底に限局して，急激な経過で直径2〜5mm程度の 小水疱が散在〜多発する（汗疱，図7.17）．さらにそれが刺激 性接触皮膚炎などを合併し，指側面や手背に拡大して瘙痒を伴